118 related articles for article (PubMed ID: 26226950)
1. Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recipients on cyclosporine A.
Sommerer C; Zeier M; Meuer S; Giese T
Clin Nephrol; 2015 Sep; 84(3):165-72. PubMed ID: 26226950
[TBL] [Abstract][Full Text] [Related]
2. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Transpl Infect Dis; 2014 Jun; 16(3):379-86. PubMed ID: 24666466
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.
Sommerer C; Hartschuh W; Enk A; Meuer S; Zeier M; Giese T
Clin Transplant; 2008; 22(5):549-54. PubMed ID: 18394001
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Ann Transplant; 2014 Jan; 19():32-40. PubMed ID: 24457606
[TBL] [Abstract][Full Text] [Related]
6. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of nuclear factor of activated T-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine a.
Herden U; Kromminga A; Hagel C; Hartleb J; Nashan B; Sterneck M; Fischer L
Ther Drug Monit; 2011 Apr; 33(2):185-91. PubMed ID: 21383649
[TBL] [Abstract][Full Text] [Related]
9. Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients.
Sommerer C; Morath C; Giese T; Meuer S; Zeier M
Transplant Proc; 2008 Jun; 40(5):1416-8. PubMed ID: 18589120
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A.
Giese T; Zeier M; Schemmer P; Uhl W; Schoels M; Dengler T; Buechler M; Meuer S
Transplantation; 2004 Feb; 77(3):339-44. PubMed ID: 14966405
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study.
Sommerer C; Brunet M; Budde K; Millán O; Guirado Perich L; Glander P; Meuer S; Zeier M; Giese T
Br J Clin Pharmacol; 2021 Oct; 87(10):3851-3862. PubMed ID: 33620734
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients.
Billing H; Giese T; Sommerer C; Zeier M; Feneberg R; Meuer S; Tönshoff B
Pediatr Transplant; 2010 Nov; 14(7):844-51. PubMed ID: 20602720
[TBL] [Abstract][Full Text] [Related]
13. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
Trials; 2014 Dec; 15():489. PubMed ID: 25494823
[TBL] [Abstract][Full Text] [Related]
14. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors.
Giese T; Zeier M; Meuer S
Nephrol Dial Transplant; 2004 Jul; 19 Suppl 4():iv55-60. PubMed ID: 15240851
[TBL] [Abstract][Full Text] [Related]
15. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients.
Sommerer C; Zeier M; Meuer S; Giese T
Transplantation; 2010 Jun; 89(11):1417-23. PubMed ID: 20463649
[TBL] [Abstract][Full Text] [Related]
16. Nuclear Factor of Activated T Cells-Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors.
Sommerer C; Giese T
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S50-6. PubMed ID: 26418701
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients.
Millán O; Ruiz P; Fortuna V; Navasa M; Brunet M
Liver Int; 2020 Apr; 40(4):931-946. PubMed ID: 31883422
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients.
Konstandin MH; Sommerer C; Doesch A; Zeier M; Meuer SC; Katus HA; Dengler TJ; Giese T
Transpl Int; 2007 Dec; 20(12):1036-43. PubMed ID: 17850236
[TBL] [Abstract][Full Text] [Related]
20. Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring: The Randomized Controlled Calcineurin Inhibitor-Sparing Trial.
Sommerer C; Brocke J; Bruckner T; Schaier M; Morath C; Meuer S; Zeier M; Giese T
Transplantation; 2018 Mar; 102(3):510-520. PubMed ID: 29077654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
